To advance AIRR-seq for clinical use, i.e. in prognosis, diagnostics, and disease monitoring. The working group strives to uncover why there has been little translation of the tremendous progress in the field of AIRR-seq into the clinics. Furthermore, the working group aims to identify and promote ways of expanding AIRR-seq techniques into general clinical use. This covers both sequencing technologies and analytical methods and will be achieved through:
- Evaluation of the usage of AIRR-seq data for diagnostic purposes. These include diagnosis, prognosis, monitoring purposes, inclusion biomarkers for clinical studies, etc.
- Identification of bottlenecks or challenges for AIRR-seq based clinical assays. These can be software tools, but also data sets or general approaches such as statistical methods, machine learning, pattern recognition, etc.
Goals
For 2024-2026:
- Advance AIRR-Seq for clinical diagnostics & monitoring
- Produce and extend reach of On AIRR
- Promote AIRR-Standard
- Finalize review
- Initialize review on ML in diagnostic AIRR-Seq – together with new Machine Learning WG
- Review AIRR-Standard fields for diagnostic purposes
- Provide a resource for endorsed tools relevant for the use of AIRR in diagnostics
Long-term vision and how WG or SC products integrate with the AIRR-C mission:
- Promoting the vision described in our perspective paper The Future of Blood Testing Is the Immunome (Front. Immunol., 15 March 2021) through community outreach and engagement
- Promoting adoption of the standards established in the Standards Working Group for a common framework for clinical classifier discovery
- Acting as an umbrella for clinic-oriented members of various AIRR-C working groups, such as the Biological Resources, Legal and Ethics and Software Working Groups, to brainstorm and promote further development and applications of AIRR-seq clinical testing (e.g. potential project design, standard data collection, software tools, extension to new diseases or uses)
- Representing a link between the AIRR-seq community and regulatory agencies regarding clinical application of AIRR-Seq
Products
- Publications submitted:
- Precision Diagnostics of Infection with Immunoprofiling, Artificial Intelligence and Medical Software – Enkelejda Miho (Submitted to The Lancet Digital Health)
- Machine learning in AIRR diagnostics: Advances and Applications – Aslı Semerci and Celine AlBalaa (Submitted as Review in Immunoinformatics)
- Challenges and Future Directions of AIRR-seq-Based Diagnostics – WG (Submitted as Perspective in Immunoinformatics)
- Podcast
- The Future of Blood Testing Is the Immunome (Front. Immunol., 15 March 2021)
- Contributions to Immunogenetics: Methods and Protocols, Methods in Molecular Biology, In press.
- Contributions to data sets shared in the AIRR Data Commons (COVID-19)
Members
Co-leaders: Pieter Meysman and Ulrik Stervbo
Members: Rohit Arora, Lmar Babrak, Rachael Bashford-Rogers, Magnolia Bostick, Felix Breden, Syed Ahmad Chan Bukhari, Brian Corrie, Lindsay Cowell, Sol Efroni, Khalil El Mazouari, Christopher Gooley , Victor Greiff, David Klatzmann, Yoshinobu Koguchi, Ton Langerak, Theam Soon Lim, Eline Luning Prak, Susanna Marquez, Pieter Meysman, Enkelejda Miho, Nima Nouri, Milena Pavlović, Florian Rubelt, Geir Kjetil Sandve, Tilman Schneider-Hohendorf, Nicholas Schwab , Erand Smakaj, Cinque Soto, Ulrik Stervbo, Johannes Trück, Henk-Jan van den Ham, Eric Waltari, and Corey Watson
